Tyrosine Kinase Inhibitor STI-571: The New Wonder Drug of Cancer Therapy?

Commentary to: Inhibition of Cell Survival and Invasive Potential of Colorectal Carcinoma Cells by the Tyrosine Kinase Inhibitor STI571 Graziella Bellone, Dario Ferrero, Anna Carbone, Marlene R. De Quadros, Claudia Gramigni, Adriana Prati, Richard Davidson, Pierroberto Mioli, Luca Dughera, Giorgio Emanuelli, and Ulrich Rodeck

[1]  M. Tulliez,et al.  Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. , 2003, Blood.

[2]  S. Ashley,et al.  The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. , 2003, The Journal of surgical research.

[3]  J. Soria,et al.  Imatinib in small cell lung cancer. , 2003, Lung cancer.

[4]  J. Szatkowski,et al.  Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. , 2003, Cancer letters.

[5]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[6]  M. Mareel,et al.  The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. , 2002, Cancer research.

[7]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.

[8]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[9]  B. Druker,et al.  Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.

[10]  P. D. Dal Cin,et al.  Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. , 2001, Cancer research.

[11]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[12]  K. Kolibaba,et al.  Protein tyrosine kinases and cancer. , 1997, Biochimica et biophysica acta.

[13]  J. Becker.  Signal transduction inhibitors—a work in progress , 2004, Nature Biotechnology.

[14]  H. Kantarjian,et al.  Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. , 2003, Blood.

[15]  J. Sierra,et al.  Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. , 2003, Haematologica.